Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more
Bioventix (BVXP) - Net Assets
Latest net assets as of June 2025: GBX11.55 Million GBX
Based on the latest financial reports, Bioventix (BVXP) has net assets worth GBX11.55 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX12.86 Million) and total liabilities (GBX1.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX11.55 Million |
| % of Total Assets | 89.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2.27% |
| 10-Year Change | 40.75% |
| Growth Volatility | 76.87 |
Bioventix - Net Assets Trend (2006–2025)
This chart illustrates how Bioventix's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioventix (2006–2025)
The table below shows the annual net assets of Bioventix from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX11.55 Million | -3.76% |
| 2024-06-30 | GBX12.00 Million | -0.51% |
| 2023-06-30 | GBX12.06 Million | +2.05% |
| 2022-06-30 | GBX11.82 Million | +0.01% |
| 2021-06-30 | GBX11.82 Million | -5.60% |
| 2020-06-30 | GBX12.52 Million | +15.65% |
| 2019-06-30 | GBX10.83 Million | -1.68% |
| 2018-06-30 | GBX11.01 Million | +8.54% |
| 2017-06-30 | GBX10.14 Million | +23.60% |
| 2016-06-30 | GBX8.21 Million | +24.65% |
| 2015-06-30 | GBX6.58 Million | +25.74% |
| 2014-06-30 | GBX5.24 Million | +24.53% |
| 2013-06-30 | GBX4.20 Million | +25.90% |
| 2012-06-30 | GBX3.34 Million | +24.74% |
| 2011-06-30 | GBX2.68 Million | +13.16% |
| 2010-06-30 | GBX2.37 Million | +178.03% |
| 2009-06-30 | GBX851.00K | +299.53% |
| 2008-06-30 | GBX213.00K | +244.90% |
| 2007-06-30 | GBX-147.00K | -107.04% |
| 2006-06-30 | GBX-71.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioventix's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16421.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX9.75 Million | 84.39% |
| Common Stock | GBX261.24K | 2.26% |
| Other Comprehensive Income | GBX1.23K | 0.01% |
| Other Components | GBX1.54 Million | 13.34% |
| Total Equity | GBX11.55 Million | 100.00% |
Bioventix Competitors by Market Cap
The table below lists competitors of Bioventix ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wells Fargo & Company PFD DIV EQUALIZ
PINK:WFCNP
|
$9.86K |
|
Valeo Pharma Inc
PINK:VPHIF
|
$9.87K |
|
DONGFENG MOTOR GP-H
MU:D4D
|
$9.87K |
|
Nam Mu Hydropower JSC
VN:HJS
|
$9.87K |
|
Rocca SA
WAR:RCA
|
$9.84K |
|
Entest Biomedical Inc
PINK:ETNI
|
$9.83K |
|
ENGEN BOTSTWANA LIMITED
XBOT:ENG-EQO
|
$9.82K |
|
JIANGSU EXPRESS -H- (JE2.SG)
STU:JE2
|
$9.81K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioventix's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,002,658 to 11,551,717, a change of -450,941 (-3.8%).
- Net income of 7,584,442 contributed positively to equity growth.
- Dividend payments of 8,194,860 reduced retained earnings.
- New share issuances of 70,254 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX7.58 Million | +65.66% |
| Dividends Paid | GBX8.19 Million | -70.94% |
| Share Issuances | GBX70.25K | +0.61% |
| Other Changes | GBX89.22K | +0.77% |
| Total Change | GBX- | -3.76% |
Book Value vs Market Value Analysis
This analysis compares Bioventix's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 664.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2721.88x to 664.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-06-30 | GBX0.53 | GBX1450.00 | x |
| 2012-06-30 | GBX0.66 | GBX1450.00 | x |
| 2013-06-30 | GBX0.84 | GBX1450.00 | x |
| 2014-06-30 | GBX1.02 | GBX1450.00 | x |
| 2015-06-30 | GBX1.28 | GBX1450.00 | x |
| 2016-06-30 | GBX1.60 | GBX1450.00 | x |
| 2017-06-30 | GBX1.95 | GBX1450.00 | x |
| 2018-06-30 | GBX2.11 | GBX1450.00 | x |
| 2019-06-30 | GBX2.07 | GBX1450.00 | x |
| 2020-06-30 | GBX2.40 | GBX1450.00 | x |
| 2021-06-30 | GBX2.25 | GBX1450.00 | x |
| 2022-06-30 | GBX2.25 | GBX1450.00 | x |
| 2023-06-30 | GBX2.28 | GBX1450.00 | x |
| 2024-06-30 | GBX2.27 | GBX1450.00 | x |
| 2025-06-30 | GBX2.18 | GBX1450.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioventix utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 65.66%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 57.83%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.11x
- Recent ROE (65.66%) is above the historical average (50.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 33.03% | 44.82% | 0.69x | 1.07x | GBX616.72K |
| 2012 | 37.05% | 51.90% | 0.67x | 1.06x | GBX903.23K |
| 2013 | 36.18% | 56.22% | 0.60x | 1.07x | GBX1.10 Million |
| 2014 | 34.67% | 51.35% | 0.61x | 1.10x | GBX1.29 Million |
| 2015 | 38.84% | 59.02% | 0.63x | 1.05x | GBX1.90 Million |
| 2016 | 42.58% | 63.34% | 0.63x | 1.07x | GBX2.67 Million |
| 2017 | 48.52% | 67.93% | 0.70x | 1.02x | GBX3.91 Million |
| 2018 | 51.43% | 64.71% | 0.74x | 1.08x | GBX4.56 Million |
| 2019 | 54.14% | 63.10% | 0.80x | 1.07x | GBX4.78 Million |
| 2020 | 57.53% | 69.84% | 0.78x | 1.06x | GBX5.95 Million |
| 2021 | 56.95% | 61.58% | 0.85x | 1.09x | GBX5.55 Million |
| 2022 | 64.92% | 65.48% | 0.89x | 1.11x | GBX6.49 Million |
| 2023 | 69.40% | 65.33% | 0.96x | 1.10x | GBX7.17 Million |
| 2024 | 67.46% | 59.51% | 0.99x | 1.14x | GBX6.90 Million |
| 2025 | 65.66% | 57.83% | 1.02x | 1.11x | GBX6.43 Million |
Industry Comparison
This section compares Bioventix's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,540,603
- Average return on equity (ROE) among peers: -153.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioventix (BVXP) | GBX11.55 Million | 33.03% | 0.11x | $9.85K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |